Garadacimab-gxii-A Novel Prophylactic Treatment for Hereditary Angioedema: A Drug Review
{{output}}
Objective: To describe garadacimab-gxii, an antibody that inhibits factor XII, indicated for hereditary angioedema (HAE) prophylaxis, approved by the Food and Drug Administration in June 2025 for patients 12 years and older. ... ...
